BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/2/2024 9:42:16 AM | Browse: 277 | Download: 1266
 |
Received |
|
2023-10-16 14:46 |
|
Peer-Review Started |
|
2023-10-16 14:48 |
|
First Decision by Editorial Office Director |
|
2023-12-06 05:03 |
|
Return for Revision |
|
2023-12-06 05:49 |
|
Revised |
|
2023-12-06 12:16 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-08 03:09 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-08 07:56 |
|
Articles in Press |
|
2024-01-08 07:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-29 00:26 |
|
Publish the Manuscript Online |
|
2024-02-02 09:42 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jia-Li Chen, Lu Guo, Zhen-Ying Wu, Kun He, Han Li, Chi Yang and Yun-Wei Han |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yun-Wei Han, MD, PhD, Professor, Researcher, Department of Oncology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou 646000, Sichuan Province, China. lanpaoxiansheng@126.com |
| Key Words |
Circulating tumor cells; Neutrophil–lymphocyte ratio; Hepatocellular carcinoma; Prognosis; Survival; Marker |
| Core Tip |
This study evaluates whether the combination of programmed death-ligand 1 on circulating tumor cells (CTCs) and the neutrophil-lymphocyte ratio can serve as a biomarker for predicting the prognosis of immune combination targeted therapy in hepatocellular carcinoma. Our study suggests the combination of CTC and neutrophil-to-lymphocyte ratio (NLR) scores as a new index for predicting survival in patients with hepatocellular carcinoma (HCC). HCC patients may benefit from pre-treatment assessment of their CTC-NLR scores for risk classification and clinical decision-making. |
| Publish Date |
2024-02-02 09:42 |
| Citation |
Chen JL, Guo L, Wu ZY, He K, Li H, Yang C, Han YW. Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(2): 372-385 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i2/372.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i2.372 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
